Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Spatial Single Cell Analysis of the Human Alzheimer's Disease Brain - Summary the Major Goal of This Project Is to Study Human Alzheimer’s Disease (AD) Brains Using the Spatial Genomics Geneps Instrument for Automated Large Scale Gene Expression Analysis at Single Cell Resolution. at Spatial Genomics, We Are Commercializing the Sequential Fluorescence in Situ Hybridization (seqfish) Technology (eng Et Al, 2019) That Allows Thousands of Genes to Be Imaged Directly in Brain Samples. We Have Experience Working With Human Brains With Our Seqfish Technology and Will Hone the Technology for Use in Human Brains. Using the Seqfish Method, We Will Identify Changes in Cell Types, Spatial Organization of Groups of Cells, and Signaling Interactions Between Neighboring Cells in the Human Ad Brain.
Committed
$2.5 Million
Paid out
$2.4M
97%
Committed, not yet paid
$75.4K
3%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…